tiprankstipranks
Pharming Group Lauded for Rare Disease Treatment
Company Announcements

Pharming Group Lauded for Rare Disease Treatment

Pharming Group Nv (PHAR) has released an update.

Don't Miss our Black Friday Offers:

Pharming Group N.V. has been recognized as an Industry Innovator at the National Organization for Rare Disorders (NORD) 2024 Rare Impact Awards for its work on Joenja®, the first FDA-approved treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare immunodeficiency. This milestone honors the company’s successful commercialization of the drug, which is now providing treatment options for adults and children over 12 with APDS, and highlights the company’s commitment to addressing rare diseases with limited therapeutic options.

For further insights into PHAR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyPharming price target lowered to EUR 1.60 from EUR 1.65 at RBC Capital
TheFlyPharming price target lowered to $30 from $31 at Oppenheimer
Brian AndersonIs PHAR a Buy, Before Earnings?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App